Intriguingly, Thio-2 inhibits AR signaling, and other important pathways, such as E2F targets, G2–M checkpoints, MYC targets V1 and MYC targets V2, implicated in the development and progression of CRPC, to inhibit the growth of treatment-resistant prostate cancer cell lines and patient-derived prostate cancer models. This evidence concerns the gene MYC and prostate carcinoma.